Integra LifeSciences Swings to Q3 Profit, Guides Q4 Revenue Below Year-Ago Levels

Integra LifeSciences Holdings Corp. (IART) reported third-quarter net income of $14.85 million, or $0.19 per share, swinging from a loss of $5.40 million, or $0.07 per share, a year earlier, the medical technology company said Wednesday. Adjusted net income rose to $46.44 million from $41.62 million, with adjusted EPS of $0.59 versus $0.54. Adjusted EBITDA increased to $79.79 million from $78.45 million, operating income jumped to $18.90 million from $11.76 million, and revenue grew to $411.18 million from $402.06 million. For the fourth quarter, the company forecasts revenue of $413 million to $433 million, a reported decline of 5.2% to 0.5%, and adjusted EPS of $0.61 to $0.71. For full-year 2026, it expects revenue of $1.634 billion to $1.654 billion, reported growth of -0.1% to 1.2%, and adjusted diluted EPS of $2.30 to $2.40. Integra shares closed Tuesday at $13.33 on the Nasdaq, down 0.89%.